Study guide
12.3 Product Storage, Labelling and Excursion Response
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
12.3 Product Storage, Labelling and Excursion Response
Key Takeaways Explain This Topic AI
Storage requirements are product-specific sponsor instructions.
A suspect excursion requires protection from inappropriate use and sponsor evaluation.
Generic temperature tables cannot establish stability of a particular batch.
Last updated: October 2026
Product Storage, Labelling and Excursion Response
Study purpose Typical scientific question Monitoring priority
Human pharmacology Exposure, tolerability and dose-related effects Dosing authorisation, timed assessments and stopping rules
Exploratory Is there evidence of activity; which regimen merits further study? Eligibility, measurement consistency and dose documentation
Confirmatory Does the evidence support the prespecified efficacy/safety objective? Reliable endpoints, safety follow-up and control of bias
Therapeutic use How does the authorised product perform with further use? Applicable surveillance, long-term outcomes and data quality
ICH E8(R1) emphasises study objectives rather than a rigid sequence. Development activities can overlap; sample sizes, durations, populations and blinding are determined by the question and product. A rare-disease confirmatory study need not enrol thousands, and an early pharmacology study need not use healthy volunteers. Study phase is a useful descriptor, not permission to skip consent, ethics review or appropriate safety oversight.
Investigational Product Accountability, Handling & Storage
Note
Investigational Product (IP) management is one of the most critical operational pillars in clinical research. Under ICH E6(R3), investigational medicinal products should have appropriate manufacturing quality and be handled, supplied, stored and used under the protocol and applicable requirements. Device-specific standards and instructions require their own appropriate controls; do not treat ICH medicinal-product guidance as a universal device manufacturing code. A complete, uncompromised chain of custody protects human participant safety and preserves the scientific integrity of trial outcomes.
In clinical research, an Investigational Product (IP) is defined as a pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial. Because investigational products have not yet received broad marketing authorization, their pharmacological profiles, physical stability limits, and toxicological risks require specialized handling protocols.
For the Clinical Research Associate (CRA), auditing pharmacy accountability logs, verifying storage conditions, investigating temperature excursions, and performing physical unit reconciliations are non-negotiable core monitoring duties.
The Investigational Product Lifecycle & Regulatory Labeling
Under ICH GCP, the investigational product lifecycle spans eight sequential stages:
Clinical Trial Packaging and Blinding
Investigational products should be packaged appropriately designed to prevent contamination, degradation, or premature unblinding during transit and storage. In double-blind studies, matching placebos or active comparators should use an appropriate masking strategy with controls against unintended disclosure.
Labelling and supply instructions
Labelling follows applicable requirements and should preserve product identification, correct use and the blind where relevant. Verify trial-specific identifiers, batch/serial or kit numbers, expiry when applicable, and storage/handling instructions. Do not assume every jurisdiction uses a US caution statement. Packaging should protect the product during handling and transport; requirements such as child resistance depend on the product and situation.
Storage Environmental Controls & Cold Chain Maintenance
Investigational products are chemically and biologically sensitive formulations. Maintaining the validated temperature range across the entire supply chain—from sponsor distribution depots to investigative site pharmacy refrigerators—is mandatory to prevent molecular degradation, protein denaturation, or toxic breakdown product formation.
Storage controls come from the product instructions
Use the sponsor's actual storage range, permitted handling time, transport requirements and stability information. Refrigeration at 2–8°C is an example for a specified product, not a universal investigational-product rule. Ambient, frozen and ultra-low conditions also vary by formulation. A CRA cannot clear an excursion from a generic temperature chart or by assuming a product that feels cold remains usable.
Monitoring devices, calibration, alarm response, backup arrangements and checking frequency should be appropriate to the product and agreed procedures. A generator is one possible continuity measure; a qualified backup storage location and a tested transfer process may be another. Establish who receives out-of-hours alerts and what happens when the first contact is unavailable. Review actual monitoring records and past excursions, not merely the presence of a thermometer.
Temperature Excursion Management Protocol
A Temperature Excursion occurs whenever the storage environment rises above or falls below the protocol-specified range for any duration of time. The CRA and site staff must execute a strict 5-step corrective response:
Warning
Quarantined investigational product must NEVER be dispensed to a trial participant under any circumstances without formal written stability clearance from the sponsor. Dispensing compromised IP violates Good Clinical Practice and exposes participants to unknown therapeutic and safety hazards.
Chain of Custody & Accountability Documentation
Investigative sites must maintain meticulous, contemporaneous written documentation accounting for every single dosage unit received, stored, dispensed, and returned.
Product recalls and restricted trial activities
E6(R3) calls for investigational product supply after the required IRB/IEC and authority approvals/favourable opinion. The sponsor should have a retrieval process for deficient recalls, expired product and other authorised returns or disposition. A monitor verifies that the applicable instructions reach the site and become traceable action.
For a batch recall, identify the affected batch/kit numbers, quantities held and participant use. Protect affected stock from further dispensing, verify required retrieval or disposition and involve the investigator for participants already exposed. Preserve accountability and relevant communication; an inventory count alone does not establish that every affected participant was evaluated. Do not independently clear replacement product or restart restricted activity because replacement boxes arrived.
An authority or sponsor restriction may affect recruitment, a cohort, a product or particular procedures. Confirm its scope, notifications and participant-care plan, then verify site implementation. Resumption requires the appropriate clearance and readiness under the actual decision. Retain safety committee recommendations and the sponsor response as relevant while protecting unblinded information from people who should remain blinded.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E8(R1) , ACRP CCRA Exam Content Outline .